Rigel Pharmaceuticals announced that pooled data from two trials, ARROW and TAPISTRY, show pralsetinib achieves a 53% overall response rate in patients with RET fusion-positive solid tumors, including lung and thyroid cancers. The drug demonstrated durable effectiveness, especially in first-line treatment for RET fusion-positive non-small cell lung cancer (NSCLC), with improved patient quality of life. These findings support pralsetinib's potential as a tumor-agnostic therapy and reinforce its role as a first-line treatment option for RET fusion-positive cancers. Further clinical data will be presented at the ESMO Congress 2026.
The news on Rigel Pharmaceuticals' pralsetinib data is presented with Pluang's Health sector market context. Of 150 priced Health-sector US stocks on Pluang, 68 rose and 54 fell today. Notable movers include Heron Therapeutics Inc (HRTX) at USD 0.37 with a 2.49% increase, Revolution Medicines Inc. (RVMD) at USD 181.96 up 2.25%, and Arrowhead Pharmaceuticals Inc. (ARWR) at USD 56.94 rising 1.86%, as of Oct 19, 2026 18:43 WIB.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
